Inhibition of the mitochondrial permeability transition by creatine kinase substrates. Requirement for microcompartmentation.
about
The cataract and glucosuria associated monocarboxylate transporter MCT12 is a new creatine transporterThe creatine kinase system and pleiotropic effects of creatineCreatine metabolism and psychiatric disorders: Does creatine supplementation have therapeutic value?Molecular system bioenergics of the heart: experimental studies of metabolic compartmentation and energy fluxes versus computer modelingSubstitution p.A350V in Na⁺/Mg²⁺ exchanger SLC41A1, potentially associated with Parkinson's disease, is a gain-of-function mutationThe creatine kinase/creatine connection to Alzheimer's disease: CK-inactivation, APP-CK complexes and focal creatine depositsC-terminal lysines determine phospholipid interaction of sarcomeric mitochondrial creatine kinaseBeneficial effects of a Q-ter based nutritional mixture on functional performance, mitochondrial function, and oxidative stress in ratsPhosphocreatine interacts with phospholipids, affects membrane properties and exerts membrane-protective effectsMitochondrial therapy for Parkinson's disease: neuroprotective pharmaconutrition may be disease-modifyingAmmonia toxicity to the brain.The advantage of channeling nucleotides for very processive functionsCombination therapy with coenzyme Q10 and creatine produces additive neuroprotective effects in models of Parkinson's and Huntington's diseases.Application of the principles of systems biology and Wiener's cybernetics for analysis of regulation of energy fluxes in muscle cells in vivo.Creatine and its potential therapeutic value for targeting cellular energy impairment in neurodegenerative diseases.Mitochondrial creatine kinase binding to phospholipid monolayers induces cardiolipin segregation.Therapeutic use of creatine in brain or heart ischemia: available data and future perspectives.Analysis of functional coupling: mitochondrial creatine kinase and adenine nucleotide translocase.Targeting cellular energy production in neurological disorders.Increased serum mitochondrial creatine kinase activity as a risk for hepatocarcinogenesis in chronic hepatitis C patients.Mitochondrial approaches to protect against cardiac ischemia and reperfusion injury.Cellular magnesium homeostasis.Creatine protects against mitochondrial dysfunction associated with HIV-1 Tat-induced neuronal injury.Novel lipid transfer property of two mitochondrial proteins that bridge the inner and outer membranesProtein changes in the retina following experimental retinal detachment in rabbits.Energy metabolism in heart failure.Creatine pretreatment protects cortical axons from energy depletion in vitro.Cardiac system bioenergetics: metabolic basis of the Frank-Starling law.Moderate elevation of intracellular creatine by targeting the creatine transporter protects mice from acute myocardial infarctionIntracellular energetic units in healthy and diseased heartsMitochondria and energetic depression in cell pathophysiologyMitochondrial therapies for Parkinson's disease.Pravastatin Chronic Treatment Sensitizes Hypercholesterolemic Mice Muscle to Mitochondrial Permeability Transition: Protection by Creatine or Coenzyme Q10.Pharmacological therapy in Parkinson's disease: focus on neuroprotection.Systems bioenergetics of creatine kinase networks: physiological roles of creatine and phosphocreatine in regulation of cardiac cell function.Molecular mechanisms of cell death: central implication of ATP synthase in mitochondrial permeability transition.The role of hexokinase in cardioprotection - mechanism and potential for translation.New insights into the trophic and cytoprotective effects of creatine in in vitro and in vivo models of cell maturation.Increasing creatine kinase activity protects against hypoxia / reoxygenation injury but not against anthracycline toxicity in vitro.Beyond muscles: The untapped potential of creatine.
P2860
Q24338344-19435847-20D4-4972-A0D5-88CBD3AF6714Q24609852-4D520D37-F504-4227-8E42-D6B10ACA52ECQ24631151-2FAEB0D3-5E0B-4175-9CF0-1C8701789374Q26851128-14AA21FB-CB72-49B7-B82A-3868B6AE1DACQ28115295-6D458618-7AFE-4586-AEEE-E13AA60E55F5Q28200789-E90C9D77-800D-4E9D-BFE4-54159F28B66DQ28252775-D7469265-5C22-43AF-81E4-C00328C1B831Q28473890-F3C57CC9-5737-4E88-B8AC-80FFD511419DQ28482353-E596E430-093F-45F2-99B4-C0EB19308305Q28732683-68F5DE04-3D66-4A2A-9E85-9871ED95B870Q30575263-BF62EBE2-BACA-4005-9997-2671BC307237Q33806597-66F33289-A412-470B-BCC8-7D1D30606183Q33837238-7906DE00-CA41-42F3-A1BC-514918D8D5BFQ33848155-F893CFEB-9465-4972-8866-0FE34FF3E79FQ33917550-01DEC912-3CB9-403B-A61D-CAA5FF34E291Q34010227-DEA84D36-543B-4DB2-AF5F-CD1FEDAE2C8CQ34089086-87ECF762-D9A7-4067-A87A-FDA2FDC9F305Q34186386-2A4CC248-1EC7-4560-BD66-26D83370DBB1Q34266266-815905D8-A483-44B0-A407-31FC16F4D2BDQ34397639-D196B43F-C878-48A8-9BA3-9BC47E479837Q34854255-3EC19924-CBE2-4A17-88FB-F60361FBDF6CQ35096887-A9AD51E3-7CB9-4A9B-A9D8-4452DE829C1CQ35215063-7352A6B8-F67C-4469-8BBB-F4C006E4BBA3Q35220127-51B699B1-08DD-405C-9FBC-0F691107377BQ35531768-77BC1C57-1D5D-4F5A-AEE2-E8D05D2D307AQ35602060-902F94BB-093D-42E8-8673-68056AC4F832Q36007434-675CC574-395C-4C70-A575-423F9F956D16Q36367258-BB73E02B-F306-4902-98A1-36F19C0A45F7Q36404972-6D5A6F94-137D-4118-A878-E3545B326FACQ37276512-90DA4A60-8B27-4115-914F-5A3CBF9A6682Q37535535-24B0A8AC-8D9C-494D-8167-89417C75C15CQ37699222-3D4BC865-DF68-4408-9121-B168DBB08BFCQ37737599-808D6B6E-14CA-41E5-8A37-737138D6024BQ37741285-5E03B4AC-32C1-4184-A848-A9F694D764B7Q37851388-2F1D9C8E-948C-47C8-947F-8D86AF3103F2Q38204222-DF2C598E-C29B-4C2A-8B41-360F87668AEDQ38247510-518ED624-2C36-46DE-ABA4-5B0A2B15E475Q38685353-FC058EA6-B160-4C0B-87DE-936AB634EE80Q38694972-2DB81A6D-F68D-4FB5-BD26-8CE97FEE8206Q38700215-8E03A9D5-F715-49D6-8D07-AD5844216286
P2860
Inhibition of the mitochondrial permeability transition by creatine kinase substrates. Requirement for microcompartmentation.
description
2003 nî lūn-bûn
@nan
2003年の論文
@ja
2003年学术文章
@wuu
2003年学术文章
@zh
2003年学术文章
@zh-cn
2003年学术文章
@zh-hans
2003年学术文章
@zh-my
2003年学术文章
@zh-sg
2003年學術文章
@yue
2003年學術文章
@zh-hant
name
Inhibition of the mitochondria ...... ent for microcompartmentation.
@en
Inhibition of the mitochondria ...... ent for microcompartmentation.
@nl
type
label
Inhibition of the mitochondria ...... ent for microcompartmentation.
@en
Inhibition of the mitochondria ...... ent for microcompartmentation.
@nl
prefLabel
Inhibition of the mitochondria ...... ent for microcompartmentation.
@en
Inhibition of the mitochondria ...... ent for microcompartmentation.
@nl
P2093
P2860
P356
P1476
Inhibition of the mitochondria ...... ment for microcompartmentation
@en
P2093
Bernd Walzel
Max Dolder
Oliver Speer
P2860
P304
17760-17766
P356
10.1074/JBC.M208705200
P407
P577
2003-03-05T00:00:00Z